Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Gordo Remartínez, Susana ^a   Calderón Moreno, María ^a   Fernández Herranz, Juan ^a   Castuera Gil, Ana ^a   Gallego Alonso Colmenares, Mar ^a   Puertas López, Carolina ^a   Nuevo González, José A ^a   Sánchez Sendín, Domingo ^a   García Gámiz, Mercedes ^a   Sevillano Fernández, José A ^a   Álvarez Sala, Luis A ^a,b   Andueza Lillo, Juan A ^a,b   De Miguel Yanes, José M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MIDREGIONAL PROADRENOMEDULLIN; PROADRENOMEDULLIN; UNCLASSIFIED DRUG; ADRENOMEDULLIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR;

AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; FEMALE; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA SEVERITY INDEX; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; BLOOD; COMMUNITY ACQUIRED INFECTION; MIDDLE AGED; PATHOLOGY; PNEUMONIA; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 84935037231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125212     Document Type: Article

References (34)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000; 31 (2):347-82. doi: 10.1086/313954 PMID: 10987697.
2. Gutiérrez Macías A, Martínez Ortiz de Zárate M. Infecciones en urgencias. Nuevos retos para el siglo XXI. Emergencias. 2000; 12:77-8.
3. Mateos Rodríguez A. Grupo para el Estudio de la Infección en Urgencias. Estudio epidemiológico de las infecciones en el Área de Urgencias. Emergencias. 2000; 12:80-9.
4. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. The European respiratory journal. 2000; 15(4):757-63. PMID: 10780770.
5. Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010; 65(10):878-83. doi: 10.1136/thx.2009.133280 PMID: 20729231.
6. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009; 64(12):1062-9. doi: 10.1136/thx.2008. 109785 PMID: 19454409; PubMed Central PMCID: PMC2782114.
7. Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. The European respiratory journal. 2011; 38(2):253-60. doi: 10.1183/09031936.00199810 PMID: 21349916.
8. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Archives of internal medicine. 2002; 162(9):1059-64. PMID: 11996618.
9. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American journal of respiratory and critical care medicine. 2001; 163(7):1730-54. doi: 10.1164/ajrccm.163.7.at1010 PMID: 11401897.
10. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection. 2004; 32(4):234-8. doi: 10.1007/s15010-004-3107-z PMID: 15293080.
11. Menéndez R T A. Aspa J Capelastegui A Prat C. Rodriguez de Castro F. Neumonía adquirida en la comunidad. Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Archivos de bronconeumologia. 2010; 46(10):543-58. PubMed Central PMCID: PMC20832928 doi: 10.1016/j.arbres.2010.06.014 PMID: 20832928
12. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3:iii1-55. doi: 10.1136/thx.2009.121434 PMID: 19783532.
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2007; 44 Suppl 2:S27-72. doi: 10.1086/511159 PMID: 17278083.
14. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England journal of medicine. 1997; 336(4):243-50. doi: 10.1056/NEJM199701233360402 PMID: 8995086.
15. Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008; 47 Suppl 3:S133-9. doi: 10.1086/591394 PMID: 18986279.
16. Aujesky D, McCausland JB, Whittle J, Obrosky DS, Yealy DM, Fine MJ. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 49(10):e100-8. doi: 10.1086/644741 PMID: 19842971.
17. Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics. 2012; 67(11):1321-5. PMID: 23184211; PubMed Central PMCID: PMC3488993.
18. Renaud B, Schuetz P, Claessens YE, Labarere J, Albrich W, Mueller B. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia. Chest. 2012; 142(6):1447-54. doi: 10.1378/chest.11-2574 PMID: 22661450.
19. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Critical care. 2010; 14(3):R106. doi: 10.1186/cc9055 PMID: 20529344; PubMed Central PMCID: PMC2911752.
20. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC infectious diseases. 2011; 11:112. doi: 10.1186/1471-2334-11-112 PMID: 21539743; PubMed Central PMCID: PMC3119069.
21. Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. The European respiratory journal. 2012; 39(5):1144-55. doi: 10.1183/09031936.00080411 PMID: 22075489.
22. Julian-Jimenez A, Timon Zapata J, Laserna Mendieta EJ, Sicilia-Bravo I, Palomo-de Los Reyes MJ, Cabezas-Martinez A, et al. Poder diagnóstico y pronóstico de los biomarcadores para mejorar el manejo de la neumonía adquirida en la comunidad en los servicios de urgencias. Enfermedades infecciosas y microbiologia clinica. 2014; 32(4):225-35. doi: 10.1016/j.eimc.2013.04.015 PMID: 24182623.
23. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Critical care. 2005; 9(6):R816-24. doi: 10.1186/cc3885 PMID: 16356231; PubMed Central PMCID: PMC1414007.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987; 40(5):373-83. PMID: 3558716.
25. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clinical chemistry and laboratory medicine: CCLM / FESCC. 2010; 48(12):1703-11. doi: 10.1515/CCLM.2010.340 PMID: 20716010; PubMed Central PMCID: PMC3155999.
26. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. The American journal of emergency medicine. 2013; 31(1):215-21. doi: 10.1016/j.ajem.2012.07.017 PMID: 23000327.
27. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. The Journal of clinical endocrinology and metabolism. 2004; 89(4):1512-25. doi: 10.1210/jc.2002-021444 PMID: 15070906.
28. Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005; 146(6):2699-708. doi: 10.1210/en.2004-1424 PMID: 15761041.
29. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009; 136(3):823-31. doi: 10.1378/chest.08-1981 PMID: 19363212; PubMed Central PMCID: PMC2818411.
30. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. American journal of respiratory and critical care medicine. 2010; 182(11):1426-34. doi: 10.1164/rccm.201003-0415OC PMID: 20639437.
31. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Annals of internal medicine. 2005; 143(12):881-94. PMID: 16365469.
32. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. The Journal of antimicrobial chemotherapy. 2010; 65(4):608-18. doi: 10.1093/jac/dkq038 PMID: 20179023.
33. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA: the journal of the American Medical Association. 2009; 302(10):1059-66. doi: 10.1001/jama.2009.1297 PMID: 19738090.
34. Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. The European respiratory journal. 2013; 42(4):1064-75. doi: 10.1183/09031936.00113612 PMID: 23349444; PubMed Central PMCID: PMC3787815.